• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, Jan. 11 Natco Pharma Ltd has bagged the approval of the Canadian Regulatory Agency (TPD-Health Canada), for its product Ondansetron 4 mg and 8 mg tablets. The approval had been accorded to Natco’s marketing partner, IP Generics, based out of Canada.

With this approval, the Hyderabad-based company can now market its products in Canada, according to a release.

The TPD-Health Canada had already approved the Citalopram Hydrobromide 20 mg and 40 mg tablets of Natco.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
ICML’s world car to hit market by 2010

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line